biostudies-literatureCortazar FBAmerican Society of NephrologyNIDDK NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesNHLBI NIH HHSNational Heart, Lung, and Blood InstituteNational Cancer InstituteNCI NIH HHSASNNIDDK435-446https://www.ebi.ac.uk/biostudies/studies/S-EPMC7003302biostudies-literatureUnknown31(2)<h4>Background</h4>Despite increasing recognition of the importance of immune checkpoint inhibitor-associated AKI, data on this complication of immunotherapy are sparse.<h4>Methods</h4>We conducted a multicenter study of 138 patients with immune checkpoint inhibitor-associated AKI, defined as a ≥2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI.<h4>Results</h4>Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently associated with an increased risk of immune checkpoint inhibitor-associated AKI. Median (interquartile range) time from immune checkpoint inhibitor Journal of the American Society of Nephrology : JASNClinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.PMC7003302P30 CA008748K23 DK117014K23DK117014K23DK106448K08DK120868R01 HL144566K08 DK118120P30CA008748K23 DK106448K08DK118120R01HL144566K08 DK120868T32 DK007219Dinh ARShin DSReynolds KLOrtiz-Melo DIRangarajan SHogan JJMamlouk OCortazar FBAbudayyeh AManohar SKitchlu AMurakami NAssal AUprety DLeaf DEMalik ABMithani ZGupta SShirali ACSharma SSise MEShirazian SKibbelaar ZAJohnson DBHerrmann SMMarrone KAGlezerman IGVijayan ARenaghan ADHosseini AMotwani SSfalseClinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.<h4>Background</h4>Despite increasing recognition of the importance of immune checkpoint inhibitor-associated AKI, data on this complication of immunotherapy are sparse.<h4>Methods</h4>We conducted a multicenter study of 138 patients with immune checkpoint inhibitor-associated AKI, defined as a ≥2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune checkpoint inhibitor. We also collected data on 276 control patients who received these drugs but did not develop AKI.<h4>Results</h4>Lower baseline eGFR, proton pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently associated with an increased risk of immune checkpoint inhibitor-associated AKI. Median (interquartile range) time from immune checkpoint inhibitor 2020-01-01T00:00:00Z2020 Feb2025-04-26T18:50:40.897Z2021-02-21T04:29:27ZS-EPMC70033023189655410.1681/ASN.201907067610.1681/asn.2019070676